Literature DB >> 1968223

Receptor reserve for 5-hydroxytryptamine1A-mediated inhibition of serotonin synthesis: possible relationship to anxiolytic properties of 5-hydroxytryptamine1A agonists.

E Meller1, M Goldstein, K Bohmaker.   

Abstract

The irreversible receptor antagonist N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ) was used to determine the relationship between receptor occupancy and response at central 5-hydroxytryptamine1A (5-HT1A) serotonin receptors mediating the inhibition of serotonin synthesis in rat cortex and hippocampus. Rats were treated with vehicle or EEDQ (2 or 6 mg/kg) and 24 hr later dose-response curves were constructed for inhibition of 5-hydroxytrytophan (5-HTP) accumulation (after decarboxylase inhibition with NSD-1015) by the selective 5-HT1A agonists 8-hydroxy-2(di-n-propylamino)tetralin (8-OH-DPAT) (0.01-3 mg/kg), buspirone (0.1-7.5 mg/kg), and ipsapirone (0.1-6.25 mg/kg) and the 5-HT1A agonist/antagonist BMY 7378 (0.015-5 mg/kg). In vehicle-pretreated rats, a similar maximal inhibition of 5-HT synthesis (range, 52-59%) was observed in both brain areas with 8-OH-DPAT, buspirone, and ipsapirone. These three agonists were also more potent in reducing 5-HTP accumulation in the cortex than in the hippocampus (ED50, 8-OH-DPAT, 14 and 30 microgram/kg; buspirone, 0.42 and 0.63 mg/kg; ipsapirone, 0.44 and 1.26 mg/kg, respectively). In the cortex, EEDQ treatment shifted the dose-response curves for 8-OH-DPAT, buspirone, and ipsapirone 8.6-, 2.0-, and 2.8-fold to the right, respectively. Corresponding rightward shifts in the hippocampus were smaller, 6.0-, 1.6-, and 2.1-fold, respectively. The EEDQ-induced shifts in the dose-response curves were accompanied by reductions in maximal response. In contrast, whereas the maximal inhibition of cortical 5-HTP accumulation by BMY 7378 (55%) was similar to that obtained with the agonists, maximal response in the hippocampus was much smaller (32%). Furthermore, in both brain regions EEDQ reduced the maximal response to BMY 7378 without shifting the dose-response curves. Analysis of the data by the double-reciprocal method of Furchgott, followed by calculation of fractional receptor occupancy for each dose of agonist, revealed a nonlinear relationship between receptor occupancy and response for 8-OH-DPAT, buspirone, and ipsapirone in both brain regions, demonstrating the presence of a large receptor reserve. For BMY 7378, in contrast, linear relationships were obtained. Because 5-HT1A receptor-mediated regulation of 5-HT synthesis appears to be mediated by somatodendritic autoreceptors on 5-HT neurons in the midbrain raphé nuclei, the results suggest that these autoreceptors possess a large receptor reserve for agonists. The relevance of these findings for the mechanism of action of nonbenzodiazepine anxiolytics is discussed.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1968223

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  40 in total

1.  RGS inhibition at G(alpha)i2 selectively potentiates 5-HT1A-mediated antidepressant effects.

Authors:  Jeffery N Talbot; Emily M Jutkiewicz; Steven M Graves; Crystal F Clemans; Melanie R Nicol; Richard M Mortensen; Xinyan Huang; Richard R Neubig; John R Traynor
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-02       Impact factor: 11.205

2.  In vivo electrophysiological and neurochemical effects of the selective 5-HT1A receptor agonist, F13640, at pre- and postsynaptic 5-HT1A receptors in the rat.

Authors:  Laia Lladó-Pelfort; Marie-Bernadette Assié; Adrian Newman-Tancredi; Francesc Artigas; Pau Celada
Journal:  Psychopharmacology (Berl)       Date:  2011-12-03       Impact factor: 4.530

3.  Agonist/antagonist interactions with cloned human 5-HT1A receptors: variations in intrinsic activity studied in transfected HeLa cells.

Authors:  H W Boddeke; A Fargin; J R Raymond; P Schoeffter; D Hoyer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-03       Impact factor: 3.000

4.  Preferential in vivo action of F15599, a novel 5-HT(1A) receptor agonist, at postsynaptic 5-HT(1A) receptors.

Authors:  L Lladó-Pelfort; M-B Assié; A Newman-Tancredi; F Artigas; P Celada
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

Review 5.  5-HT(1A) receptor function in major depressive disorder.

Authors:  Jonathan Savitz; Irwin Lucki; Wayne C Drevets
Journal:  Prog Neurobiol       Date:  2009-02-07       Impact factor: 11.685

6.  The role of serotonergic mechanisms in inhibition of isolation-induced aggression in male mice.

Authors:  C Sánchez; J Arnt; J Hyttel; E K Moltzen
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

7.  Delayed effects of spiperone on serotonin1A receptors in the dorsal hippocampus of rats.

Authors:  T Dennis; P Blier; C de Montigny
Journal:  J Psychiatry Neurosci       Date:  1993-11       Impact factor: 6.186

8.  The stimulatory effect of clonidine through imidazoline receptors on locus coeruleus noradrenergic neurones is mediated by excitatory amino acids and modulated by serotonin.

Authors:  J A Ruiz-Ortega; L Ugedo; J Pineda; J A García-Sevilla
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-08       Impact factor: 3.000

9.  The novel 5-HT1A receptor antagonist, SDZ 216-525, decreases 5-HT release in rat hippocampus in vivo.

Authors:  T Sharp; R McQuade; J R Fozard; D Hoyer
Journal:  Br J Pharmacol       Date:  1993-07       Impact factor: 8.739

10.  GH4ZD10 cells expressing rat 5-HT1A receptors coupled to adenylyl cyclase are a model for the postsynaptic receptors in the rat hippocampus.

Authors:  C J Fowler; P C Ahlgren; G Brännström
Journal:  Br J Pharmacol       Date:  1992-09       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.